Long-term use of a topical antibiotic application at central venous catheter (CVC) exit sites in hemodialysis (HD) patients may result in a sustained decrease in all CVC-related infections, according ...
Intravascular catheter-related bloodstream infections are a major cause of morbidity and mortality in the United States. In the intensive care unit (ICU), the rate of central venous catheter ...
Surgically placed central venous catheters (CVC) are increasingly being replaced by percutaneous CVC (PCVC) for nutritional and fluid support of neonates. (Durand, Pediatrics, 1986) We report ...
Please provide your email address to receive an email when new articles are posted on . Using data from the US Renal Data System, researchers identified 74,194 Medicare-eligible patients who initiated ...
Please provide your email address to receive an email when new articles are posted on . Study findings indicated that although most patients who had insurance before developing end-stage renal disease ...
A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks No significant financial ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results